{
    "root": "316b0bb6-c15c-c1d0-e063-6394a90aabb4",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "XARELTO",
    "value": "20250328",
    "ingredients": [
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "POLYETHYLENE GLYCOL 3350",
            "code": "G2M7P15E5P"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "RIVAROXABAN",
            "code": "9NDF7JZ4M3"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "ANHYDROUS CITRIC ACID",
            "code": "XF417D3PSL"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "CARBOXYMETHYLCELLULOSE SODIUM, UNSPECIFIED",
            "code": "K679OBS311"
        },
        {
            "name": "SODIUM BENZOATE",
            "code": "OJ245FE5EU"
        },
        {
            "name": "SUCRALOSE",
            "code": "96K6UQ3ZD4"
        },
        {
            "name": "XANTHAN GUM",
            "code": "TTV12P4NEE"
        }
    ],
    "indications": "XARELTO is a factor Xa inhibitor indicated: to reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation ( 1.1 ) for treatment of deep vein thrombosis (DVT) ( 1.2 ) for treatment of pulmonary embolism (PE) ( 1.3 ) for reduction in the risk of recurrence of DVT or PE ( 1.4 ) for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery ( 1.5 ) for prophylaxis of venous thromboembolism (VTE) in acutely ill medical patients ( 1.6 ) to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) ( 1.7 ) to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD ( 1.8 ) for treatment of VTE and reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years ( 1.9 ) for thromboprophylaxis in pediatric patients 2 years and older with congenital heart disease after the Fontan procedure ( 1.10 )",
    "contraindications": "Nonvalvular Atrial Fibrillation : 15 or 20 mg, once daily with food ( 2.1 ) Treatment of DVT and/or PE : 15 mg orally twice daily with food for the first 21 days followed by 20 mg orally once daily with food for the remaining treatment ( 2.1 ) Reduction in the Risk of Recurrence of DVT and/or PE in patients at continued risk for DVT and/or PE : 10 mg once daily with or without food, after at least 6 months of standard anticoagulant treatment ( 2.1 ) Prophylaxis of DVT Following Hip or Knee Replacement Surgery : 10 mg orally once daily with or without food ( 2.1 ) Prophylaxis of VTE in Acutely Ill Medical Patients at Risk for Thromboembolic Complications Not at High Risk of Bleeding : 10 mg once daily, with or without food, in hospital and after hospital discharge for a total recommended duration of 31 to 39 days ( 2.1 ) CAD or PAD : 2.5 mg orally twice daily with or without food, in combination with aspirin (75–100 mg) once daily ( 2.1 ) Pediatric Patients: See dosing recommendations in the Full Prescribing Information ( 2.2 )",
    "warningsAndPrecautions": "XARELTO\n       \n \n  ® (rivaroxaban) Tablets are available in the strengths and packages listed below:\n      \n\n \n                  \n                     2.5 mg tablets are round, light yellow, and film-coated with a triangle pointing down above a \"2.5\" marked on one side and \"Xa\" on the other side. The tablets are supplied in the packages listed: \t\t\t\t\t\t\t\n        \n  \n   \n                           \n                           \n                           \n                              \n                                 NDC 50458-577-60\n                                 Bottle containing 60 tablets\n                              \n                              \n                                 NDC 50458-577-18\n                                 Bottle containing 180 tablets\n                              \n                              \n                                 NDC 50458-577-10\n                                 Blister package containing 100 tablets (10 blister cards containing 10 tablets each)\n                              \n                           \n                        \n                     \n                     10 mg tablets are round, light red, biconvex film-coated tablets marked with a triangle pointing down above a \"10\" on one side, and \"Xa\" on the other side. The tablets are supplied in the packages listed: \t\t\t\t\t\t\t\n        \n  \n   \n                           \n                           \n                           \n                              \n                                 NDC 50458-580-30\n                                 Bottle containing 30 tablets\n                              \n                              \n                                 NDC 50458-580-90\n                                 Bottle containing 90 tablets\n                              \n                              \n                                 NDC 50458-580-10\n                                 Blister package containing 100 tablets (10 blister cards containing 10 tablets each)\n                              \n                           \n                        \n                     \n                     15 mg tablets are round, red, biconvex film-coated tablets with a triangle pointing down above a \"15\" marked on one side and \"Xa\" on the other side. The tablets are supplied in the packages listed: \t\t\t\t\t\t\t\n        \n  \n   \n                           \n                           \n                           \n                              \n                                 NDC 50458-578-30\n                                 Bottle containing 30 tablets\n                              \n                              \n                                 NDC 50458-578-90\n                                 Bottle containing 90 tablets\n                              \n                              \n                                 NDC 50458-578-10\n                                 Blister package containing 100 tablets (10 blister cards containing 10 tablets each)\n                              \n                           \n                        \n                     \n                     20 mg tablets are triangle-shaped, dark red film-coated tablets with a triangle pointing down above a \"20\" marked on one side and \"Xa\" on the other side. The tablets are supplied in the packages listed: \t\t\t\t\t\t\t\n        \n  \n   \n                           \n                           \n                           \n                              \n                                 NDC 50458-579-30\n                                 Bottle containing 30 tablets\n                              \n                              \n                                 NDC 50458-579-90\n                                 Bottle containing 90 tablets\n                              \n                              \n                                 NDC 50458-579-89\n                                 Bulk bottle containing 1000 tablets\n                              \n                              \n                                 NDC 50458-579-10\n                                 Blister package containing 100 tablets (10 blister cards containing 10 tablets each)\n                              \n                           \n                        \n                     \n                     Starter Pack for treatment of deep vein thrombosis and treatment of pulmonary embolism: \t\t\t\t\t\t\t\n        \n  \n   \n                           \n                           \n                           \n                              \n                                 NDC 50458-584-51\n                                 30-day starter blister pack containing 51 tablets: 42 tablets of 15 mg and 9 tablets of 20 mg\n                              \n                           \n                        \n                     \n                  \n                  XARELTO\n       \n \n  ® (rivaroxaban) for oral suspension is available in the strength and package listed below:\n      \n\n \n                  \n                     \n                     \n                     \n                        \n                           NDC 50458-575-01\n                           Supplied as white to off-white granules in an amber glass bottle containing 155 mg rivaroxaban packaged with two oral dosing syringes. After reconstitution with 150 mL of purified water, 1 mL of the suspension contains 1 mg rivaroxaban.",
    "adverseReactions": "XARELTO is contraindicated in patients with:\n                  \n                     active pathological bleeding \n        \n  \n   [see \n         \n   \n    Warnings and Precautions (5.2)]\n        \n  \n   \n                     \n                     severe hypersensitivity reaction to XARELTO (e.g., anaphylactic reactions) \n        \n  \n   [see \n         \n   \n    Adverse Reactions (6.2)]"
}